Frontlight ResearchEarly access
Taking people in NetherlandsPhase 2/3
Contrast ultrasound to find sentinel nodes in melanoma, breast, or head and neck cancer
Tests contrast ultrasound for locating sentinel lymph nodes in adults with cancer.
Key facts
- Who runs it
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
- Where
- Amsterdam, NetherlandsSee the site
- Trial code
- Registry title
- Contrast-enhanced ultrasound for sentinel node detection in patients with melanoma, breast cancer or head & neck cancer
- Status
- Recruiting
- Phase
- Phase 2/3
- People taking part
- 91 people, planned
- Started
- 7 Jul 2025
- Planned end
- 7 Oct 2025
- Type of study
- Interventional
- Record updated
- 9 December 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with melanoma, breast cancer or head and neck cancer who are scheduled for a sentinel node operation at the NKI-AvL.
- Age
- 18 years or older
- Sex
- All sexes can join.
- Disease stage
- Cancer of the skin (melanoma), breast, or head and neck. A melanoma must be in the limbs or in the head and neck area.
Main reasons for not taking part
- Pregnancy
- Known serious allergic reaction to the study medication, such as eggs or egg products
- Other reasons the Sonazoid contrast agent cannot be used, such as a heart or lung shunt, serious coronary artery disease or serious lung disease
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- Aged 18 years or older
- Patient has been diagnosed with cancer in the skin (melanoma), breast or head & neck (including melanoma of head and neck area)
- In case of a melanoma: it should be located in the limbs or head and neck area
- Scheduled for a surgical SN procedure at the NKI-AvL
- Patient provides written informed consent
Who cannot take part
- Any known clinically significant acute hypersensitivity reaction to the study medication, such as eggs or egg products
- Other contra-indications for Sonazoid contrast agent, including arteriovenous cardiac or pulmonary shunt, serious coronary arterial disease and serious pulmonary disease
- Pregnancy
Where in Netherlands
- Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis StichtingAmsterdam, NetherlandsTaking people
About the trial
What the trial wants to find out
To assess the sensitivity and specificity of CEUS for intra-operative SN localization compared to the gold standard (99mTc nanocolloid).
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).
- Official title
- Contrast-enhanced ultrasound for sentinel node detection in patients with melanoma, breast cancer or head & neck cancer (N24CUS)
- Plain-language title
- Contrast ultrasound to find sentinel nodes in melanoma, breast, or head and neck cancerGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 9 December 2024